Roche committed $700 million upfront to partner with Nurix on bexobrutideg, an oral BTK degrader for B-cell malignancies, with milestones that could increase the total to $2.3 billion. The companies’ structure splits US profits evenly during development and commercialization, while Roche handles ex-US commercialization and pays Nurix tiered royalties. The collaboration sets up head-to-head positioning against Eli Lilly’s Jaypirca in phase 3.